ROS1+ Cancer Innovation Award
The ROS1ders organization is now accepting applications for the 2025 ROS1+ Cancer Innovation Award, which provides up to $75,000 for one year to support pre-clinical, translational, or clinical research that advances understanding and treatment of ROS1-positive cancer. This rare subset of cancer affects approximately 1–2% of non-small cell lung cancers and other tumor types.
Why this matters:
Although there are approved targeted therapies for ROS1+ cancer, they don’t work for all patients, and resistance eventually develops. There is an urgent need for deeper insights into ROS1 biology and more effective, long-term treatment options.
Who is eligible?
Applicants must:
-
Hold a doctoral degree (MD, PhD, or equivalent)
-
Have a faculty appointment at a research institution
-
Be based anywhere in the world
-
Propose a high-risk, high-reward project directly relevant to ROS1+ cancer
Funding at a glance:
-
$75,000 total
-
1-year duration
-
Intended to fund innovative, impact-focused research
-
Up to 3 awards will be granted in 2025
Research focus:
Projects should aim to:
-
Improve understanding of ROS1+ cancer biology
-
Develop or optimize diagnostics or treatments
-
Enhance quality of life or survival outcomes for ROS1+ patients
Key deadlines (all 11:59 PM ET):
-
Full Application Deadline: June 23, 2025
-
Award Notification: September 30, 2025
Where to apply:
Submit via ProposalCentral. Templates and full RFA details are available there. Be sure to review instructions carefully for updates.
More information:
Visit www.ros1der.org or contact the foundation for access to the full RFA and press release.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023